MX2013005819A - Benzoxazepinas como inhibidores de 3-cinasa/objetivo mamífero de rapamicina (pi3k/mtor) metodos de uso y fabricacion. - Google Patents

Benzoxazepinas como inhibidores de 3-cinasa/objetivo mamífero de rapamicina (pi3k/mtor) metodos de uso y fabricacion.

Info

Publication number
MX2013005819A
MX2013005819A MX2013005819A MX2013005819A MX2013005819A MX 2013005819 A MX2013005819 A MX 2013005819A MX 2013005819 A MX2013005819 A MX 2013005819A MX 2013005819 A MX2013005819 A MX 2013005819A MX 2013005819 A MX2013005819 A MX 2013005819A
Authority
MX
Mexico
Prior art keywords
inhibitors
pi3k
mtor
methods
benzoxazepines
Prior art date
Application number
MX2013005819A
Other languages
English (en)
Inventor
Kenneth Rice
Original Assignee
Exelixis Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Exelixis Inc filed Critical Exelixis Inc
Publication of MX2013005819A publication Critical patent/MX2013005819A/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing three or more hetero rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
    • A61K31/553—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole having at least one nitrogen and one oxygen as ring hetero atoms, e.g. loxapine, staurosporine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Oncology (AREA)
  • Hematology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Epidemiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Nitrogen And Oxygen As The Only Ring Hetero Atoms (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
  • Plural Heterocyclic Compounds (AREA)

Abstract

La invención se refiere a los inhibidores de PI3K y mTOR y sales o solvatos farmacéuticamente aceptables de éstos, así como los métodos de su uso, en donde los inhibidores presentan la Fórmula I estructural. (Fórmula) y sales farmacéuticamente aceptables de éstos, en donde las variables se definen como en la presente.
MX2013005819A 2010-11-24 2011-11-23 Benzoxazepinas como inhibidores de 3-cinasa/objetivo mamífero de rapamicina (pi3k/mtor) metodos de uso y fabricacion. MX2013005819A (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US41714210P 2010-11-24 2010-11-24
PCT/US2011/062029 WO2012074869A1 (en) 2010-11-24 2011-11-23 Benzoxazepines as inhibitors of pi3k/mtor and methods of their use and manufacture

Publications (1)

Publication Number Publication Date
MX2013005819A true MX2013005819A (es) 2013-08-27

Family

ID=45217715

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2013005819A MX2013005819A (es) 2010-11-24 2011-11-23 Benzoxazepinas como inhibidores de 3-cinasa/objetivo mamífero de rapamicina (pi3k/mtor) metodos de uso y fabricacion.

Country Status (11)

Country Link
US (1) US20140005172A1 (es)
EP (1) EP2643319A1 (es)
JP (1) JP2013544827A (es)
KR (1) KR20140000706A (es)
CN (1) CN103402999A (es)
AU (1) AU2011336882A1 (es)
CA (1) CA2818882A1 (es)
EA (1) EA201390755A1 (es)
MX (1) MX2013005819A (es)
WO (1) WO2012074869A1 (es)
ZA (1) ZA201303758B (es)

Families Citing this family (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2012037204A1 (en) 2010-09-14 2012-03-22 Exelixis, Inc. Inhibitors of pi3k-delta and methods of their use and manufacture
BR112014010492A2 (pt) 2011-11-01 2017-04-25 Exelixis Inc n-(3-{[(3-{[2-cloro-5-(metóxi)fenil]amino}quinoxalin-2-il)amino]sulfonil}fenil)-2-metilalaninamida como inibidor de fosfatidilinositol 3-cinase para o tratamento de malignidades linfoproliferativas
TWI597061B (zh) * 2013-02-20 2017-09-01 國鼎生物科技股份有限公司 治療白血病之方法及組成物
HUE057970T2 (hu) 2018-03-08 2022-06-28 Incyte Corp Aminopirazindiol-vegyületek mint PI3K-Y inhibitorok
US11046658B2 (en) 2018-07-02 2021-06-29 Incyte Corporation Aminopyrazine derivatives as PI3K-γ inhibitors
WO2020124397A1 (en) * 2018-12-19 2020-06-25 Inventisbio Shanghai Ltd. C-terminal src kinase inhibitors
CA3231246A1 (en) * 2021-09-10 2023-03-16 Alessandro Boezio Pi3k-alpha inhibitors and methods of use thereof

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN101395155A (zh) * 2005-10-07 2009-03-25 埃克塞里艾克西斯公司 PI3Kα的吡啶并嘧啶酮抑制剂
WO2008108445A1 (ja) * 2007-03-07 2008-09-12 Takeda Pharmaceutical Company Limited ベンゾオキサゼピン誘導体およびその用途
US20100305093A1 (en) * 2009-04-09 2010-12-02 Exelixis, Inc. Inhibitors of mTOR and Methods of Making and Using
WO2010135568A1 (en) * 2009-05-22 2010-11-25 Exelixis, Inc. Benzoxazepines as inhibitors of mtor and their use to treat cancer
KR20120034666A (ko) * 2009-05-22 2012-04-12 엑셀리시스, 인코포레이티드 증식성 질환에 대한 벤족사제핀 기반 ｐ１３ｋ／ｍｔ０ｒ의 억제제
CA2763008A1 (en) * 2009-05-26 2010-12-02 Exelixis, Inc. Benzoxazepines as inhibitors of pi3k/mtor and methods of their use and manufacture
WO2012071519A1 (en) * 2010-11-24 2012-05-31 Exelixis, Inc. Benzoxazepines as inhibitors of p13k/mtor and methods of their use and manufacture

Also Published As

Publication number Publication date
EP2643319A1 (en) 2013-10-02
EA201390755A1 (ru) 2013-11-29
AU2011336882A1 (en) 2013-06-20
US20140005172A1 (en) 2014-01-02
CA2818882A1 (en) 2012-06-07
KR20140000706A (ko) 2014-01-03
JP2013544827A (ja) 2013-12-19
ZA201303758B (en) 2014-04-30
WO2012074869A8 (en) 2013-07-18
WO2012074869A1 (en) 2012-06-07
CN103402999A (zh) 2013-11-20

Similar Documents

Publication Publication Date Title
MX2013005826A (es) Benzoxazepinas como inhibidores de fosfatidilinositol 3-cinasa/objetivo de rapamicina en mamiferos (p13k/mtor) y metodos de uso y fabricacion.
PH12019501321B1 (en) Use of pyrazolopyrimidine derivatives for the treatment of pi3k-delta related disorders
WO2012071509A3 (en) Benzoxazepines as inhibitors of p13k/mtor and methods of their use and manufacture
WO2012068106A3 (en) Benzoxazepines as inhibitors of pi3k/mtor and methods of their use and manufacture
WO2012068096A3 (en) Benzoxazepines as inhibitors of pi3k/mtor and methods of their use and manufacture
MX2019010602A (es) Inhibidores de cdk.
IN2015DN01156A (es)
PH12014501417A1 (en) Dihydro-benzo-oxazine and dihydro-pyrido-oxazine derivatives
SG190819A1 (en) Nampt and rock inhibitors
WO2014028600A3 (en) 3-AMINOCYCLOALKYL COMPOUNDS AS RORgammaT INHIBITORS AND USES THEREOF
WO2010135524A8 (en) Benzoxazepines based p13k/mt0r inhibitors against proliferative diseases
MX336381B (es) Boronatos como inhibidores de arginasa.
MX351464B (es) El uso de un agonista del receptor 8 tipo toll para el tratamiento de enfermedades alérgicas.
MX341456B (es) Amino-quinolinas como inhibidores de cinasa.
TN2012000578A1 (en) Tetrahydro-pyrido-pyrimidine derivatives
PH12015500376A1 (en) Novel bicyclic pyridinones
EA201491149A1 (ru) Пиразолопиридиновые производные, способы их получения и их терапевтическое применение
IN2015DN01151A (es)
MX2013005819A (es) Benzoxazepinas como inhibidores de 3-cinasa/objetivo mamífero de rapamicina (pi3k/mtor) metodos de uso y fabricacion.
MX2013002851A (es) Inhibidores de tonum pectinacetilesterasa y metodos de su uso.
MX2013008340A (es) Novedosas 4-amino-n-hidroxi-benzamidas para el tratamiento de cancer.
EA201491227A1 (ru) Новые производные морфолинила, подходящие для применения в качестве ингибиторов mogat-2
EA201590656A1 (ru) Азаиндолины
MX2013005825A (es) Benzoxazepinas como inhibidores de objetivo de rapamicina en mamiferos (mtor) y metodos de uso y fabricacion.
MX359399B (es) Inhibidores de 17alfa-hidroxilasa/c17-20-liasa.

Legal Events

Date Code Title Description
FA Abandonment or withdrawal